AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Sean Caenepeel, Sean P Brown, Brian Belmontes, Gordon Moody, Kathleen S Keegan, Danny Chui, Douglas A Whittington, Xin Huang, Leszek Poppe, Alan C Cheng, Mario Cardozom, Jonathan Houze, Yunxiao Li, Brian Lucas, Nick A Paras, Xianghong Wang, Joshua P Taygerly, Marc Vimolratana, Manuel Zancanella, Liusheng Zhu Show all
Cancer Discovery | AMER ASSOC CANCER RESEARCH | Published : 2018
Awarded by Australian National Health and Medical Research Council [Department of Community Services and Health (DCSH)]
Awarded by Leukemia and Lymphoma Society (SCOR grants)
Awarded by Australian National Health and Medical Research Council [Independent Research Institutes Infrastructure Support Scheme]
This work was supported by Amgen Inc. BAK<SUP>-/-</SUP>BAX<SUP>-/-</SUP> cell line experiments were supported by scholarships, fellowships, and grants from the Australian National Health and Medical Research Council [NHMRC; Research Fellowships to A.W. Roberts and the Department of Community Services and Health (DCSH); Project Grants to DCSH 1057742; Program Grants 1016647, 1016701; Independent Research Institutes Infrastructure Support Scheme grant 9000220], the Cancer Council Victoria (grant-in-aid to A.W. Roberts and DCSH), the Leukemia and Lymphoma Society (SCOR grants 7001-13), the Australian Cancer Research Foundation, and a Victorian State Government Operational Infrastructure Support grant. The authors thank Jin Tang for assistance with protein purification and Victor Cee for critical evaluation of the manuscript. Ben Scott, PhD (Scott Medical Communications, LLC), and Beate Quednau, PhD (Amgen Inc.), provided medical writing assistance funded by Amgen Inc.